Renpu Pharmaceuticals Ltd. is a Sino-British enterprise; headquartered in Biobay, Suzhou Industrial Park. Renpu Pharma was established at 2010 with 15 million RMB registered capital. Renpu Pharma is dedicating to R&D, production and sale of ocean fish product - unsaturated fatty acid Omega - 3 related drugs and nutraceuticals. Now it has become a premium supplier in the industry.

R&D team in Renpu Pharma is full of passionate and aggressive talents. Four senior members hold PhD degree (three of them are returnees). The consultancy team in Renpu Pharma is led by Professor Chai Zhi Fang, academician, Chinese Academy of Science, and a number of well known scientists from Chinese academic institutions and oversea experts in drug development. Renpu Pharma has established and maintained a long term partnership with famous institutions like the Institute of High Energy Physics and the Institute of Biophysics from Chinese Academy of Sciences; the Graduate school of the Chinese Academy of Sciences, Soochow University, Imperial College London, etc.

With devoted research and development, Renpu Pharma has developed highly efficient & reproducible processes and advanced equipment for the scaled up production of high purity EPA/DHA fish oil. Our production technology of ultra-pure EPA (chemical purity≥96%) is the leading level in both China and worldwide. Our high quality raw materials mainly originate from Peru, Chile and Iceland, using our unique technique to remove harmful impurities including heavy metal, dioxin, PCBs, etc. Our Omega-3 series APIs and intermediates comply with different region’s standard and the most stringent industry monograph. Our products have approved by our European, US, Japanese and Korean clients.

In addition to Omega-3 intermediate and APIs, Renpu is working on commercialization of Omega-3 EPA/DHA/DPA microspheres, which are next generation Omega-3 products in solid formulation with application in every aspect of functional food and nutrition. This project is developed by Renpu’s sister company ------Jiangsu Yuekang Biotechnology Co., Ltd. Omega-3 microsphere product in series is about to be launched very shortly.

At the end of 2021, a new product jointly developed by Renpu and Xinhua Pharma has been successfully launched on the market. Zebai EPA works on reducing high triglyceride levels thus protecting your heart.

 The product has been certified by the US FDA and European EMA for its clinical lipid-lowering effect.

Renpu Pharma is committed to the concept -“Purest”, we will continue optimizing our process to provide the best quality Omega – 3 products for the treatment of cardiovascular diseases, also the key ingredients as food additive and functional products.